These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12783599)

  • 1. Farnesyl transferase inhibitors in clinical development.
    Caponigro F; Casale M; Bryce J
    Expert Opin Investig Drugs; 2003 Jun; 12(6):943-54. PubMed ID: 12783599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
    Doll RJ; Kirschmeier P; Bishop WR
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):478-86. PubMed ID: 15338957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
    Adjei AA; Erlichman C; Davis JN; Cutler DL; Sloan JA; Marks RS; Hanson LJ; Svingen PA; Atherton P; Bishop WR; Kirschmeier P; Kaufmann SH
    Cancer Res; 2000 Apr; 60(7):1871-7. PubMed ID: 10766174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM; Khuri FR
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
    Karp JE
    Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl transferase inhibitors for patients with lung cancer.
    Johnson BE; Heymach JV
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4254s-4257s. PubMed ID: 15217969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
    Dempke WC
    Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
    Cortes JE; Kurzrock R; Kantarjian HM
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):26-30. PubMed ID: 12214290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of clinical trials of farnesyltransferase inhibitors.
    Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
    Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.